Missouri is currently home to 1892 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479
Recruiting
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Register for Updates
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478
Recruiting
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Washington University, School of Medicine, Saint Louis, Missouri
Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
Register for Updates
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729
Recruiting
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
NCT06013241
Recruiting
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: USA011, Columbia, Missouri
Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Register for Updates
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT06008093
Recruiting
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/17/2025
Locations: Research Site, Kansas City, Missouri
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211
Recruiting
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
04/17/2025
Locations: Children's Mercy Hospital Kansas City, Kansas City, Missouri
Conditions: Single Ventricle Heart Disease
Register for Updates
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
NCT05784246
Recruiting
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
04/17/2025
Locations: St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Ulcerative Colitis
Register for Updates
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/17/2025
Locations: MediSearch Clinical Trials, Saint Joseph, Missouri
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Register for Updates
Study of M5049 in DM and PM Participants (NEPTUNIA)
NCT05650567
Recruiting
The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: University of Kansas Medical Center-Neuromuscular, Kansas City, Missouri
Conditions: Dermatomyositis, Polymyositis
Register for Updates
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of Missouri Hospital, Columbia, Missouri
Conditions: Breast Neoplasms
Register for Updates
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Washington University School of Medicine, Infectious Diseases Clinical Research Unit, Saint Louis, Missouri
Conditions: Candidemia, Candidiasis, Invasive
Register for Updates
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
NCT05304962
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Cancer
Register for Updates